The short version
- Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- What the evidence isNo human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
- What to watchChest pain or racing heart.
How SLU-PP-915 works
Start with the thing this site's own card gets wrong. SLU-PP-915 is not an ERR-alpha-selective analog of SLU-PP-332.
What those receptors are. ERR-alpha, ERR-beta and ERR-gamma are orphan nuclear receptors. Orphan means no endogenous ligand has been identified: they sit on DNA constitutively active, and what normally regulates their output is not a hormone but the availability of a coactivator — PGC-1-alpha, the protein exercise itself induces.
Louis University series. Estrogen-related receptors are orphan nuclear receptors that sit at the top of the mitochondrial biogenesis program — agonizing them upregulates oxidative metabolism and fatty acid oxidation, which is why the class gets called an 'exercise mimetic'. The selectivity is the point: SLU-PP-332 hits ERR alpha, beta and gamma, and the beta/gamma activity is where a lot of the cardiac concern sits.
- Oral
On the goal map: Exercise mimetics & mitochondrial biogenesis (Endurance & work capacity)
Research on SLU-PP-9155 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Preclinical (rodent) only.
Human clinical evidence
No human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
No completed human trial
Correlative data
Newer than SLU-PP-332 and with an even thinner record — there is essentially no practical use to report, and what circulates is extrapolation from the earlier compound rather than experience with this one.
How the mechanism reads
A selective ERRα agonist, developed from the SLU-PP-332 scaffold specifically to improve on it — better selectivity for ERRα over ERRβ and ERRγ, and improved pharmacokinetics.
MechanisticReported to increase thermogenesis and drive conversion of white adipose toward a beige, thermogenic phenotype in rodent work.
Experimental, animal or cellSelectivity is the design case and the untested claim. ERRγ is highly expressed in cardiac tissue, so sparing it is the argument for a better safety margin — which is a prediction from receptor binding data, not a demonstrated outcome.
Mechanistic
Sources
- Hampton CS, Sitaula S, Billon C, Haynes K, Avdagic A, Wanninayake U, Adeyemi CM, Chatterjee A, Griffett K, Banerjee S, Burris SL, Schoepke E, Boehm T, Bess A, de Vera IMS, Burris TP, Walker JK. Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915.. Eur J Med Chem 2023 · PMID 37421886
- Billon C, Appourchaux K, Cote I, Burris TP. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity.. J Pharmacol Exp Ther 2025 · PMID 41421047
- Moller T, Krug O, Thevis M. In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential.. Rapid Commun Mass Spectrom 2026 · PMID 41588687
- Billon C. Synthetic ERRalpha/beta/gamma Agonist Induces an ERRalpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.. ACS Chem Biol 2023 · PMID 36988910
- Billon C. A Synthetic ERR Agonist Alleviates Metabolic Syndrome.. J Pharmacol Exp Ther 2023 · PMID 37739806
- Xu W, Billon C, Li H, Wilderman A, Qi L, Graves A, Rideb JRDC, Zhao Y, Hayes M, Yu K, Losby M, Hampton CS, Adeyemi CM, Hong SJ, Nasiotis E, Fu C, Oh TG, Fan W, Downes M, Welch RD, Evans RM, Milosavljevic A, Walker JK, Jensen BC, Pei L, Burris T, Zhang L. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.. Circulation 2023 · PMID 37961903
SLU-PP-915 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Breast or prostate cancer history: ERR alpha is the isoform most often high in those tumors.
- Pregnancy: ERR alpha helps run placental energy metabolism.
- Heart or kidney disease: ERR alpha drives oxidative metabolism in both organs.
- Under 18: an energy-metabolism receptor switch in growing bodies has no data.
- Wanting a human-tested route: rodent studies used an oral form, with no human data.
What’s expected
- Human effects are unknown, since only rodent work exists.
- If ERR alpha is switched on: more fat and fatty-acid oxidation in muscle.
- Possible tiredness as energy metabolism reprograms.
Watch for
- Chest pain or racing heart.
- Aching muscles with tea-colored urine after starting an ERR alpha agonist.
- Unplanned weight loss.
- New breathlessness.
Labs that tell you it’s working
- Comprehensive Metabolic Panel (CMP)
- Lipid Panel
- Cystatin C with eGFR
- Insulin (Fasting)
SLU-PP-915 is a more ERR-alpha-selective analog of SLU-PP-332; selectivity narrows the receptor but remains untested in people. PMID 37421886 PMID 41421047
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
SLU-PP-915 FAQ4 common questions
- Is SLU-PP-915 approved for human use?
- No. SLU-PP-915 is a research compound. No completed randomized human trial has given it yet.
- What is SLU-PP-915 researched for?
- Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- Which labs show whether it's doing anything?
- Comprehensive Metabolic Panel; Lipid Panel; Cystatin C with eGFR; Insulin: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for SLU-PP-915: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



